Research Data (IMAGE)
Caption
Sequencing data from 188 sGBM patients were collected to uncover the mutational landscape of sGBM, which reveals METex14 as a biomarker for predicting patient survival. In Phase I MET-targeted clinical trial, partial response was achieved in selected patients.
Credit
HKUST
Usage Restrictions
None
License
Licensed content